- Verubecestat – ALZFORUM
Background MK-8931 is a small-molecule inhibitor of BACE1 and BACE2. BACE1 is the β-secretase enzyme that cleaves the APP protein to release the C99 fragment of APP, which gives rise to various specie …
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β …
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med. 2016 Nov 2;8 (363):363ra150.
At High Doses, BACE1 Inhibitors Hinder Synaptic Plasticity …
Participants in Merck’s Phase 2/3 trial are receiving daily doses of 12, 40, or 60 mg of MK-8931. However, a direct comparison between mouse and human doses is not practical, Filser said, because the …
Vanquishing Brain Cancer: A New Mission for BACE inhibitors?
First author Kui Zhai and colleagues happened upon verubecestat, aka MK-8931, while searching for ways to rouse TAMs into destroying glioma cells. The BACE inhibitor emerged as a top candidate in a sc …
ALZFORUM | NETWORKING FOR A CURE
Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
BACE Inhibitor Heads for Phase 2/3 Trials | ALZFORUM
The news comes after Merck’s December 2013 announcement that its inhibitor MK-8931 had cleared safety hurdles in its Phase 2/3 study (see Dec 2013 news story). Other BACE inhibitors are in earlier sta …
BACE Inhibition and the Synapse—Insights from Seeon
In Seeon, Herms said that they have since seen the same effect with other BACE inhibitors, including MK-8931, which is being tested in Phase 2/3 clinical trials. After 21 daily doses of this drug, the …
Therapeutics Search | ALZFORUM
Amyloid-Related Small Molecule Alzheimer's Disease
Lilly Teams Up With AstraZeneca for BACE Inhibitor Phase 2/ …
In the once-crowded field of BACE inhibitors, only Merck’s MK-8931 maintains a lead on AZD3293, having passed initial safety benchmarks in its own Phase 2/3 EPOCH study last year (see Dec 2013 news st …
Clinical Trials on Alzheimer's Disease 2017 | ALZFORUM
A Phase 3 trial of verubecestat, aka MK-8931, in prodromal AD is ongoing. Above all, many scientists at CTAD emphasized that negative trials are important. “Negative studies occur in most fields, and …
コメント